Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR23303771

—

2731320f-f8c0-57f8-bd90-42bb9063578f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.550
  • MTORC1_SIGNALING+0.470
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
  • E2F_TARGETS+0.420
  • G2M_CHECKPOINT+0.380
  • PROTEIN_SECRETION+0.370
  • OXIDATIVE_PHOSPHORYLATION+0.360
  • MYC_TARGETS_V2+0.330
  • ANGIOGENESIS+0.310
  • P53_PATHWAY+0.290

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.310
  • INTERFERON_GAMMA_RESPONSE-0.230
  • IL2_STAT5_SIGNALING-0.170
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
  • HEDGEHOG_SIGNALING-0.100
  • UV_RESPONSE_DN-0.080
  • APICAL_JUNCTION-0.070
  • COMPLEMENT-0.070
  • CHOLESTEROL_HOMEOSTASIS-0.060
  • COAGULATION-0.060

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-0322
medullo-epn-umap@date-based
MedMedulloblastoma0.844
2TCGA-18-4086-01A-01R-1100-07
lung-landscapes@6
—cohortSQ20.827
3TCGA-B6-A0IK-01A-12R-A056-07
breast-umap@18
—C0.827
4TCGA-33-4586-01A-01R-1443-07
lung-landscapes@6
—cohortSQ20.809
5TCGA-66-2759-01A-01R-0851-07
lung-landscapes@6
—cohortSQ20.807
6s0122203
melanoma-umap@29
——0.800
7TCGA-66-2727-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.799
8TCGA-22-5485-01A-01R-1635-07
lung-landscapes@6
—cohortSQ20.797
9MDT-AP-3285
medullo-epn-umap@date-based
MedMedulloblastoma0.795
10MNG432
mng-umap@100
——0.794

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.550Inavolisib— uncovered
MTORC1_SIGNALING0.470Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.470Inavolisib— uncovered
E2F_TARGETS0.420Inavolisib— uncovered
G2M_CHECKPOINT0.380Inavolisib— uncovered
PROTEIN_SECRETION0.370Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.360Remibrutinib— uncovered
MYC_TARGETS_V20.330Idelalisib— uncovered
ANGIOGENESIS0.310Remibrutinib— uncovered
P53_PATHWAY0.290Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.290Idelalisib— uncovered
DNA_REPAIR0.260Idelalisib— uncovered
ADIPOGENESIS0.220Inavolisib— uncovered
GLYCOLYSIS0.200Inavolisib— uncovered
ANDROGEN_RESPONSE0.190Inavolisib— uncovered
FATTY_ACID_METABOLISM0.180Inavolisib— uncovered
HEME_METABOLISM0.130Temsirolimus— uncovered
MITOTIC_SPINDLE0.130Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.130Inavolisib— uncovered
UV_RESPONSE_UP0.110Idelalisib— uncovered